Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9 Normal Saline Clear all

Conditions: Allergic Conjunctivitis
Interventions: ST266, Saline (0.9% NaCl); Biological · Drug
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Andover, Massachusetts • Memphis, Tennessee

Conditions: COVID-19
Interventions: SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 12
States / cities: Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more

Conditions: Neuroendocrine Tumors in Lung
Interventions: Lanreotide (Autogel formulation), Placebo, Best Supportive Care; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 14
States / cities: Tucson, Arizona • Los Angeles, California • Denver, Colorado + 11 more

Conditions: Pain
Interventions: 1% Diclofenac Sodium, 3% Menthol, 0.09% Menthol, 0.2% Sodium Lauryl Sulfate, 0.9% Saline; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Type 2 Diabetes Mellitus
Interventions: Bexagliflozin; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years to 55 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Sunburn
Interventions: 6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation, 6% Bemotrizinol (BEMT) dispersion in petrolatum, Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT, Petrolatum vehicle, 0.9% Saline, Sodium Lauryl Sulfate 0.1% (SLS), Undosed patch; Drug · Other
Lead sponsor: dsm-firmenich Switzerland AG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Chemotherapy-induced Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Interventions: Tetrodotoxin, Placebo; Drug
Lead sponsor: Wex Pharmaceuticals Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 15
States / cities: Santa Ana, California • Santa Rosa, California • Port Charlotte, Florida + 11 more

Conditions: Shigella, Diarrhea
Interventions: IVT Shigella-04, Placebo (0.9% saline); Biological
Lead sponsor: Inventprise Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Obesity
Interventions: Angiotensin-(1-7), Saline; Drug
Lead sponsor: Amy Arnold; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Postoperative Pain, Hip Arthroscopy
Interventions: Preop PENG block, Placebo block, Ropivacaine 0.5% Injectable Solution, Normal Saline; Procedure · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Tendonitis;Achilles
Interventions: Micronized DHACM, Saline Injection; Biological · Drug
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 14
States / cities: Birmingham, Alabama • Tucson, Arizona • Carlsbad, California + 10 more

Conditions: Ischemia Reperfusion Injury
Interventions: Conjugated Estrogen, Normal saline; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Opioid-use Disorder, Chronic Pain Syndrome
Interventions: Naloxone Hydrochloride, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Suicidal Ideation, Depression, Alcohol Abuse
Interventions: Intranasal ketamine, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 21 Years to 60 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
Interventions: Certolizumab Pegol, Placebo; Biological · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more

Conditions: Sepsis, Severe
Interventions: CYT107, Placebos; Biological · Drug
Lead sponsor: Revimmune; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Gainesville, Florida • St Louis, Missouri

Conditions: Pain
Interventions: Ketamine 0.15mg/kg, Ketamine 0.3mg/kg, Placebo; Drug · Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Pain, Postoperative
Interventions: Single shot interscalene nerve block, Continuous interscalene nerve block, Local Infiltration Analgesia (LIA); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Colorectal Disease
Interventions: bupivacaine, normal saline placebo (for bupivacaine); Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cytomegalovirus Infection
Interventions: mRNA-1647, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 315 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 9
States / cities: Sacramento, California • Peoria, Illinois • Lenexa, Kansas + 5 more

Conditions: Pain
Interventions: Topical gel vehicle, Sodium lauryl sulfate 0.1%, Sodium chloride solution 0.9% (saline); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Carlstadt, New Jersey

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: 20mM sodium pyruvate nasal spray, Saline Placebo control nasal spray; Drug · Other
Lead sponsor: Cellular Sciences, inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Hialeah Gardens, Florida

Conditions: Dystocia
Interventions: Oxytocin, Sodium Chloride 0.9%; Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,003 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cervical Dystonia
Interventions: DaxibotulinumtoxinA for injection, Placebo; Biological
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 44
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 38 more

Search by objective public record fields.

Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel

Absolute Bioavailability Study With Bexagliflozin

Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain

First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults

Angiotensin-(1-7) and Energy Expenditure in Human Obesity

PENG Block for Arthroscopic Hip Surgery

Micronized dHACM Injectable for the Treatment of Achille Tendonitis

Intravenous Estrogen in Kidney Transplant Study

The Effect of Chronic Pain on Delay Discounting in Methadone Patients

Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients

Low Dose Ketamine for Management of Acute Severe Pain in the Emergency Department

Analgesic Efficacy of Interscalene Nerve Block Versus Local Infiltration Analgesia Following Total Shoulder Arthroplasty

Evaluation of a TAP Block Given During Laparoscopic Colorectal Surgery to Help Control Pain

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

RIPT of Ibuprofen Topical Gel

The Effect of N115 on Coughing in IPF Patients

Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation

Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)